GLP-1 vs GLP-2 vs GLP-3: Which Peptide Protocol Is Right for Your Goal?
If you’ve spent any time researching peptides for metabolic health or performance, you’ve run into the GLP family. GLP-1 gets most of the mainstream attention right now largely driven by clinical applications in metabolic medicine. But GLP-2 and GLP-3 operate through entirely different mechanisms and serve distinct purposes that are often overlooked in the noise around their more famous sibling.
This guide is for people who want to understand the difference before making a decision, not after. We’ll break down each compound, what the research says about its primary action, and which goal profile it’s most relevant for.
Understanding the GLP Framework
GLP stands for Glucagon-Like Peptide. These are endogenous peptides meaning your body produces versions of them naturally that are derived from the proglucagon gene. Despite sharing that common origin, the three variants bind to different receptors and trigger meaningfully different downstream responses.
That’s the key point to hold onto as we move through each one: same family, fundamentally different functions.
GLP-1: The Metabolic Regulator
What the Research Shows
GLP-1 (Glucagon-Like Peptide-1) is the most extensively studied of the three. It is an incretin hormone, meaning it is released in response to food intake and plays a central role in regulating postprandial glucose levels. When GLP-1 binds to its receptor found in the pancreas, brain, stomach, and heart it stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and signals satiety to the central nervous system.
The clinical research base for GLP-1 receptor agonism is substantial. Studies have documented significant effects on fasting glucose, HbA1c levels, body weight, and cardiovascular risk markers in metabolically compromised populations.
Who It’s Most Relevant For
GLP-1 is the most appropriate starting point for anyone whose primary goals center on metabolic regulation, appetite control, or body composition management. Its dual action on both glucose metabolism and central satiety signaling makes it a uniquely versatile compound within the GLP family.
If your focus is on reducing caloric intake more sustainably, supporting insulin sensitivity, or addressing the metabolic underpinnings of body composition GLP-1 is where the evidence is strongest and the research depth is greatest.
GLP-2: The Gut Integrity Specialist
What the Research Shows
GLP-2 (Glucagon-Like Peptide-2) acts primarily on the gastrointestinal system. Its receptor is expressed predominantly in intestinal epithelial cells, where GLP-2 signaling promotes mucosal growth, enhances nutrient absorption, reduces intestinal permeability, and supports the structural integrity of the gut lining.
Research has explored GLP-2 in the context of conditions characterized by compromised intestinal barrier function including short bowel syndrome, where a synthetic GLP-2 analogue has achieved regulatory approval. But within the performance and wellness research community, interest has grown around its potential role in supporting gut health in athletes who experience exercise-induced intestinal permeability, a documented phenomenon in endurance and high-intensity training populations.
Who It’s Most Relevant For
GLP-2 fits a very different profile from GLP-1. If your primary concerns are gut function, nutrient absorption efficiency, recovery from gastrointestinal stress, or supporting intestinal integrity during periods of intense physical training, GLP-2 is the more targeted option.
It is not a metabolic or appetite-signaling compound in the way GLP-1 is. The two serve distinct systems, and conflating them based on shared nomenclature leads to poor protocol decisions.
GLP-3: The Emerging Research Compound
What the Research Shows
GLP-3 (Glucagon-Like Peptide-3) is the least characterized of the three in published literature, which makes it simultaneously the most intriguing and the most requiring of caution. It is produced from the same proglucagon precursor as GLP-1 and GLP-2, but its distinct receptor binding profile and downstream signaling are still being actively mapped by researchers.
Early investigation has pointed toward potential interactions with intestinal L-cells and possible roles in enteroendocrine signaling, though the full picture of its physiological function remains an active area of inquiry. For this reason, GLP-3 is classified and positioned as a research-grade compound appropriate for structured investigational use rather than general wellness application.
Who It’s Most Relevant For
GLP-3 is best suited for researchers, practitioners, and highly informed users operating within formal research frameworks who have a specific interest in enteroendocrine biology and are equipped to document and evaluate outcomes methodically.
If you are newer to peptide protocols, or your goals are primarily performance or body composition driven, GLP-1 or GLP-2 offer a more established evidence base and better-characterized risk profiles for your starting point.
Side-by-Side Comparison
| GLP-1 (S) | GLP-2 (T) | GLP-3 (R) | |
| Primary System | Metabolic / CNS | Gastrointestinal | Enteroendocrine |
| Key Action | Insulin regulation, appetite suppression | Gut lining integrity, nutrient absorption | Under active investigation |
| Best Goal Fit | Body composition, metabolic health | Gut function, training recovery | Structured research use |
| Evidence Depth | Extensive | Substantial | Emerging |
The Protocol Decision: Where to Start
The most common mistake people make with the GLP family is choosing based on name recognition rather than mechanism match. GLP-1 dominates headlines right now, but that doesn’t make it the right compound for every goal.
Ask yourself one question before you decide: what system am I actually trying to support? If the answer is metabolic regulation and appetite GLP-1. If the answer is gut integrity and nutrient efficiency GLP-2. If you are conducting structured research into enteroendocrine signaling — GLP-3.